Lynparza is the only PARP inhibitor to improve overall survival versus enzalutamide or abiraterone in prostate cancer patients with BRCA1/2 or ATM mutations More: AZ/MSD's Lynparza wins prostate cancer approval Source: News
read moreGilead to start selling remdesivir in coming weeks, expects ‘multi-year commercial opportunity’ aliu Wed, 05/20/2020 – 10:58 More: Gilead to start selling remdesivir in coming weeks, expects 'multi-year commercial opportunity' Source: fierce
read moreCiting a COVID-19 portfolio review—not lawsuits—J&J pulls baby powder from U.S. market esagonowsky Wed, 05/20/2020 – 09:48 More: Citing a COVID-19 portfolio review—not lawsuits—J&J pulls baby powder from U.S. market Source: fierce
read moreNew Zolgensma ‘inflection point’ is here as Novartis snags EU nod for SMA gene therapy aliu Wed, 05/20/2020 – 07:28 More: New Zolgensma 'inflection point' is here as Novartis snags EU nod for SMA gene therapy Source: fierce
read moreThe overall death rate for people with diabetes doubled during the early stage of the pandemic More: People with diabetes at higher risk of amid pandemic Source: News
read moreAstraZeneca and Merck’s Lynparza pressures Clovis’ Rubraca with prostate cancer OK chelfand Tue, 05/19/2020 – 19:03 More: AstraZeneca and Merck's Lynparza pressures Clovis' Rubraca with prostate cancer OK Source: fierce
read more© 1994 - 2026 B.M. Pharmaceuticals